Please login to the form below
Evan Lippman joins Aileron Therapeutics
He has experience at EMD Serono, Pfizer and AstraZeneca
Aileron Therapeutics has added to its senior team with the appointment of Evan Lippman as its first chief financial and business officer.
The addition comes as the US biopharma prepares to advance its lead oncology candidate ALRN-6924 into clinical trials.
In Lippman Aileron gains the expertise of a man with great experience in life sciences. Most recently Lippman help a senior VP role at EMD Serono heading the strategy for its US neurology franchise.
Highlights of his career include a spell as executive director at AstraZeneca where he led on huge brands such as Crestor (rosuvastatin calcium) and Nexium (esomeprazole) and heading US business development at the same company.
Lippman's other big pahrma experience includes a period at Pfizer as executive director, worldwide business development and strategic planning.
Featured jobs
-
Director – Healthcare PR
-
Salary TBC
-
Associate Director, Healthcare PR
-
£60, 000 – £67, 000+ benefits
-
Senior Medical Writer
-
Great salary and bebefits
- Medical Writer - Medical Communications
-
£30, 000 - £40, 000 according to skills and experience plus benefits
- Senior Account Manager / Account Director
-
Great salary and bebefits
- CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...
-
EXCELLENT DAY RATES AVAILABLE
- Sales & Marketing Manager - New Launch - Mental Health - S E...
-
Highly Competitive Basic, Bonus &Benefits
- Assistant Product Manager - Hertfordshire
-
Competitive salary depending on experience benefits
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
-
Scientific Engagement Director
-
Salary will be dependant on experience
-
Scientific Director
-
Great salary and bebefits
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
-
Product Manager - Hertfordshire
-
Competitive salary depending on experience benefits
- Senior Account Director or Business Unit Director, Healthcare Ad...
-
C£60, 000 – £70, 000 benefits
Subscribe to our email news alerts
- Novo Nordisk expands cell therapy R&D, says type 1 diabetes cure a step closer
- Immuno-oncology at ASCO: survival data, combinations and new indications
- Novartis, Amgen set low price for first CGRP migraine drug
- Moving annual total (MAT)
- Key success factor (KSF)
- Janssen named ‘Pharma Company of the Year’ at business intelligence awards
- We can be heroes
- What does ‘digital’ look like for global pharma Learning & Development?
- FDA starts review of Sanofi’s oral type 1 diabetes drug
- Is the pharma business model ready for precision medicine?
- Porterhouse Medical announces another well-deserved promotion within the group
- FDA clears Dova drug for liver-related low blood platelets
PMHub
BASTARD . LONDON
BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...
Latest intelligence
- Is the pharma business model ready for precision medicine?
- Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
- The NHS and ABPI at 70: inching closer to the triple win
- The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
- What pharma marketers can learn from behavioural science
- Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....
Quick links
Infographics
